Stents, Blood Thinners Star At Stroke Meeting
In this International Stroke Conference wrap-up, Larry Goldstein, MD, from Duke University, highlights some of the more exciting and important clinical studies presented here.
Goldstein, who heads Duke's Stroke Center, told MedPage Today cardiology editor Chris Kaiser that, although the excitement generated during meetings has to be tempered with caution, some of the news from the Crescent City has important clinical implications.
That's especially true of the new findings about restenosis rates from the CREST trial, he said.
Goldstein also noted the importance of a study that examined dual antiplatelet therapy to reduce the risk of recurrent stroke, as well as one that tested whether warfarin or aspirin could reduce stroke in heart failure patients.